Status:

COMPLETED

Alteration in Timing of Plerixafor Administration

Lead Sponsor:

Emory University

Collaborating Sponsors:

Genzyme, a Sanofi Company

Conditions:

Autologous Transplantation

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

Typically, the collection of blood cells for autologous stem cell transplant is done after the drugs granulocyte colony-stimulating factor (G-CSF) and plerixafor have been given to activate the bone m...

Eligibility Criteria

Inclusion

  • Age 18-70 years
  • MM patients in first or second complete or partial remission
  • ECOG performance status of 0 or 1
  • Up to 3 prior treatment regimens
  • Meet all eligibility requirements for autologous transplant
  • Adequate marrow function defined as WBC \>3,000; ANC \>1,500/mm3 ; Platelets \>75,000/mm3
  • Adequate renal function defined as creatinine clearance \> 30 mL/min by Cockcroft-Gault
  • Adequate liver function defined as AST/ALT/Bilirubin \< 2 times upper limit of normal
  • Able to provide informed consent
  • Women not pregnant and agree to use contraception

Exclusion

  • High risk co-morbidities for acute treatment complications (e.g., symptomatic coronary artery disease)
  • Brain metastases or carcinomatous meningitis
  • Previous treatment with high dose chemotherapy and autologous transplant.
  • Previous attempt to collect B-HPCs following mobilization with growth factors alone, growth factors and chemotherapy, or plerixafor and growth factors.
  • Acute infection or unexplained fever \>38°C
  • Weight \> 175% of ideal body weight as defined by the Devine equation.
  • Experimental therapy within 4 weeks
  • Cytokine administration in the previous 14 days

Key Trial Info

Start Date :

June 1 2010

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

Estimated Enrollment :

34 Patients enrolled

Trial Details

Trial ID

NCT01149863

Start Date

June 1 2010

Last Update

December 13 2013

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Emory University Winship Cancer Institute

Atlanta, Georgia, United States, 30322

Alteration in Timing of Plerixafor Administration | DecenTrialz